TLR2 and pertussis: We previously demonstrated that LP-GMP, which combines TLR2 and STING agonists, is a potent adjuvant when used in a novel pertussis vaccine, and conferred sterilizing immunity in the nasal mucosa, especially when delivered by the i.n. route20.